This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cacciapuoti, A.
Right arrow Articles by Loebenberg, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cacciapuoti, A.
Right arrow Articles by Loebenberg, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 638-642, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.638-642.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Interaction between Posaconazole and Amphotericin B in Concomitant Treatment against Candida albicans In Vivo

Anthony Cacciapuoti,* Maya Gurnani, Judith Halpern, Christine Norris, Reena Patel, and David Loebenberg

Schering-Plough Research Institute, Kenilworth, New Jersey

Received 26 May 2004/ Returned for modification 20 July 2004/ Accepted 28 September 2004

The interaction of posaconazole and amphotericin B was evaluated in concomitant treatment of Candida albicans systemic infections in immunocompetent mice by using four strains of C. albicans with different susceptibilities to fluconazole. Posaconazole and amphotericin B were each tested at four dose levels alone and in all possible combinations against each C. albicans strain. Survival curves of mice treated with combinations of posaconazole and amphotericin B were statistically compared with those of mice treated with the component monotherapies. Of the 64 total combinations evaluated against the C. albicans strains (16 combinations per strain), 20.3% were more effective in prolonging mouse survival than both of the monotherapies, 45.3% were more effective than one of the monotherapies, and 32.8% were similar to both monotherapies. No evidence of antagonism was observed between posaconazole and amphotericin B in this mouse model, consistent with in vitro results against the same strains.

* Corresponding author. Mailing address: Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Phone: (908) 740-3139. Fax: (908) 740-3918. E-mail: anthony.cacciapuoti{at}spcorp.com.

Antimicrobial Agents and Chemotherapy, February 2005, p. 638-642, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.638-642.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • ESPOSITO, V., VIGLIETTI, R., GARGIULO, M., PARRELLA, R., ONOFRIO, M., SANGIOVANNI, V., AMBROSINO, D., CHIRIANNI, A. (2009). Successful Treatment of Cryptococcal Meningitis with a Combination of Liposomal Amphotericin B, Flucytosine and Posaconazole: Two Case Reports. In Vivo 23: 465-468 [Abstract] [Full Text]  
  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Perkhofer, S., Lugger, H., Dierich, M. P., Lass-Florl, C. (2007). Posaconazole Enhances the Activity of Amphotericin B against Aspergillus Hyphae In Vitro. Antimicrob. Agents Chemother. 51: 791-793 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»